Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
about
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapyUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine modelHigh-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferationAnthracycline- and trastuzumab-induced cardiotoxicity: a retrospective studyTwo-dimensional strain echocardiography for detection of cardiotoxicity in breast cancer patients undergoing chemotherapy.Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysisAnthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care.Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction.Tunable visible and near-IR photoactivation of light-responsive compounds by using fluorophores as light-capturing antennas.Cardio-oncology: what you need to know now for clinical practice and echocardiography.P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.High Throughput Screening Identifies a Novel Compound Protecting Cardiomyocytes from Doxorubicin-Induced DamageMesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fearsLifestyle interventions for cardiovascular risk reduction in women with breast cancer.Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac ToxicityCardiotoxic heart failure in breast cancer survivors: a concept analysis.Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formationA novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitroPattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy.Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.Broad targeting of resistance to apoptosis in cancer.Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study.Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-CardiomyocytesRisk factors for anthracycline-associated cardiotoxicity.Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer.High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factorsNanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells.EXercise to prevent AnthrCycline-based Cardio-Toxicity (EXACT) in individuals with breast or hematological cancers: a feasibility study protocolChemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.Vitamin B12: a tunable, long wavelength, light-responsive platform for launching therapeutic agents.Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox.Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging?Anthracycline-Induced Cardiomyopathy in Adults.The Far Side of Vascular Injury: Nonconventional Vasoconstrictors, DNA-targeting Agents, and Agents Toxic to Vascular Smooth Muscle.The modulation of carbonyl reductase 1 by polyphenols.
P2860
Q26743433-32495578-02EF-418C-B096-53701AF0A8ECQ27027354-DACDCCA0-5DEF-47A3-9A56-A1555482BCA4Q28535709-D7CECF65-6925-4A48-80E3-1A86997F1305Q28540089-09735740-D70F-4EC3-948E-EB18DA652B5BQ30276527-B1E61142-F58F-4445-8DB4-484B776520AAQ33593674-22BDB479-B27D-4A90-94CE-7D7106A86564Q33657779-4B9F48D0-A73C-43DD-ACD4-2A07C9B6909AQ33658456-942BCAE5-2692-477E-8A64-5543C77B11ECQ33660939-595473AA-C493-4427-A42F-C637DA15A9E2Q33677893-7344F87F-3C7F-448F-8F11-DC00F7DF9C74Q33701308-2050A338-186A-4D2B-8841-C4270CCEFF3AQ34048273-63BCFAC7-3C4E-4496-80B1-90868456DA8DQ35681478-EDE4C1FD-FE2F-4BBC-9150-9D129FEBF53BQ35774310-43054018-7797-48AF-A57D-AC43622DC227Q35878469-AD3AB85C-E281-4EE2-B433-3F0FAEBEB047Q35999766-AD441CD0-79B9-4A82-8B88-C22AD582E4E6Q36002576-C087653A-A57B-4839-A6B6-6CD21F715CBFQ36070463-DCCD562E-D07E-4002-9D50-B0368213AAA1Q36110948-F0050F36-2AFE-463D-B42C-44F4BC68F7A1Q36163330-18A97612-808B-4080-96F4-6513EEF2219FQ36441535-546024F3-B45A-4876-AFF8-F8379785EFCAQ36451899-52E65EE4-477C-4E5F-A271-45E7B9004A00Q36483749-9C8D90A2-1088-4A0A-8A39-786A2C239A7DQ36829069-AB8661A9-C207-4BCA-9A7C-F59A82FC83AEQ36864827-8B220FD2-59FB-4C32-8394-475B866A12E0Q36921775-91D3BF36-6B46-4BAF-BE22-1ABBFAF6BE79Q37174738-441F653C-7854-437A-B40E-728A2FB6A471Q37314505-32E43979-AA9A-402C-8FAE-B904366548C1Q37420053-48C7C443-3C92-44D6-B1BB-039FB1D6ADC4Q37493509-80FDA9D8-FD00-4DE4-A6E4-E0C7E97BAEC7Q37497677-06C91B4C-9F54-4824-A94C-A3A33024E512Q37547962-E1FD828F-38B8-443C-9A5A-6764A5E032ADQ37589818-177DBFA8-E415-4D91-B724-00EC3F9F370DQ37704467-759AE9E1-A13D-4D07-B329-E24112C8857DQ38163389-B0FEC5C2-47AA-4B50-97A7-D7579217906DQ38197031-3E4C37AB-145A-45C5-9B1F-DF30AF672FAFQ38225977-269B819D-D735-47BA-8AEB-4BA5C5C01615Q38542462-156FCE42-DDC4-414D-9D13-F1FC0287C29EQ38583684-801E5541-4A56-4D75-803A-4109BEE6037DQ38594695-FF154350-6D0A-4465-AA62-38D98B1F8F78
P2860
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@ast
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@en
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@nl
type
label
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@ast
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@en
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@nl
prefLabel
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@ast
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@en
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@nl
P2860
P921
P1476
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
@en
P2093
Maria Volkova
Raymond Russell
P2860
P304
P356
10.2174/157340311799960645
P577
2011-11-01T00:00:00Z